
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals is experiencing strong revenue and earnings growth, with 1H26 revenue increasing by 22% year-over-year and adjusted EBITDA increasing by 26% year-over-year. In addition, the company's diagnostics franchise, particularly Illuccix, is gaining market share, and the company's therapeutics pipeline continues to progress toward value-inflecting datasets. With multiple diagnostic approvals and expansions on the horizon, as well as a strong pipeline of therapeutics, Telix is positioned for future success and its shares are currently undervalued.
Bears say
Telix Pharmaceuticals is projected to see a significant growth in its pipeline with its radiopharmaceuticals targeting cancer, which could potentially increase the company's revenue in the future. However, its current earnings are heavily dependent on the US sales of Illuccix as an imaging agent, leaving the company vulnerable to potential market shifts. Additionally, its valuation based on a sum-of-parts and discounted future sales projections may be inflated and not entirely reflective of the current financial health of the company.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares